SPINOCEREBELLAR ATAXIAS
Clinical trials for SPINOCEREBELLAR ATAXIAS explained in plain language.
Never miss a new study
Get alerted when new SPINOCEREBELLAR ATAXIAS trials appear
Sign up with your email to follow new studies for SPINOCEREBELLAR ATAXIAS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug trial aims to slow progression of rare movement disorder
Disease control OngoingThis study is testing whether a daily medication called troriluzole can help slow the worsening of movement, balance, and speech problems in adults with inherited spinocerebellar ataxia (SCA). About 300 participants with specific types of SCA will take either troriluzole or a pla…
Matched conditions: SPINOCEREBELLAR ATAXIAS
Phase: PHASE3 • Sponsor: Biohaven Pharmaceuticals, Inc. • Aim: Disease control
Last updated Apr 02, 2026 04:12 UTC
-
Real-World data tests Drug's 3-Year impact on rare brain disorder
Disease control OngoingThis study aims to see if the drug troriluzole can slow the progression of spinocerebellar ataxia (SCA), a rare genetic disorder that affects movement and coordination, over three years. It compares data from about 909 people who took the drug in a previous long-term study to dat…
Matched conditions: SPINOCEREBELLAR ATAXIAS
Sponsor: Biohaven Therapeutics Ltd. • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC